AMENDMENT 2 to the PATENT ASSIGNMENT AGREEMENTPatent Assignment Agreement • August 7th, 2024 • FibroBiologics, Inc. • Pharmaceutical preparations
This Amendment 2, by and between SpinalCyte LLC, a Texas limited liability company (“SpinalCyte”), and FibroBiologics, Inc., a Delaware corporation (“FibroBiologics”), (“Amendment 2”), amends the Patent Assignment Agreement dated May 17, 2021, entered into by and between SpinalCyte and FibroBiologics (as amended, the “Assignment”), and is effective as of May 17, 2021 (“Effective Date”). FibroBiologics and SpinalCyte are each referred to individually as a “Party” and collectively as the “Parties.”
AMENDMENT 1 to the INTELLECTUAL PROPERTY CROSS-LICENSE AGREEMENTCross-License Agreement • August 7th, 2024 • FibroBiologics, Inc. • Pharmaceutical preparations
This Amendment 1, by and between SpinalCyte LLC, a Texas limited liability company (“SpinalCyte”), and FibroBiologics, Inc., a Delaware corporation (“FibroBiologics”), (“Amendment 1”), amends the Intellectual Property Cross-License Agreement dated May 17, 2021, entered into by and between SpinalCyte and FibroBiologics (the “License”), and is effective as of May 17, 2021 (“Effective Date”). FibroBiologics and SpinalCyte are each referred to individually as a “Party” and collectively as the “Parties.”
